Lithosphere Deploys MultX to Enable Atomic Cross-Chain Execution on Makalu 
American Aires Inc. Announces Change of Auditor 
Zhibao Technology Announces 1H2026 Earnings Conference Call and Investor Webinar Participation 
Integrated Quantum Technologies Announces Non-Brokered Private Placement of Units 
TechCon Global Announces Dr. Irwin Jacobs as Recipient of the TechCon Fellows Lifetime Achievement Award SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences
SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid…
SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences
SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid…
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in…
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in…
Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market
Influid Water-soluble Nanotechnology Avicanna’s Patent-Pending Influid Technology Inside Viola Water-Soluble THC Infuser Developed through Avicanna’s…
Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market
Influid Water-soluble Nanotechnology Avicanna’s Patent-Pending Influid Technology Inside Viola Water-Soluble THC Infuser Developed through Avicanna’s…
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent…
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent…
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…
Agra Ventures’ Boundary Bay Cannabis JV Receives Over $910,000 in Purchase Orders in Last 3 Months
While Boundary Bay Cannabis Received Demand for Over 725,000 Grams of High-Quality Bulk Cannabis in…
Agra Ventures’ Boundary Bay Cannabis JV Receives Over $910,000 in Purchase Orders in Last 3 Months
While Boundary Bay Cannabis Received Demand for Over 725,000 Grams of High-Quality Bulk Cannabis in…
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:…
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:…
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High…
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High…
ALX Oncology Appoints Scott Garland to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
ALX Oncology Appoints Scott Garland to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
Trevena Regains Compliance with Nasdaq Listing Requirements
CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company…
Trevena Regains Compliance with Nasdaq Listing Requirements
CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company…